US Stock MarketDetailed Quotes

NKGN NKGEN BIOTECH

Watchlist
  • 1.140
  • -0.100-8.06%
Close May 14 16:00 ET
  • 1.150
  • +0.010+0.88%
Post 19:58 ET
25.64MMarket Cap-300P/E (TTM)

About NKGEN BIOTECH Company

NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression. The company was founded by Sangwoo Park in 2017 and is headquartered in Santa Ana, CA.

Company Profile

SymbolNKGN
Company NameNKGEN BIOTECH
Listing DateOct 2, 2023
Founded2017
CEOMr. Paul Song
MarketNASDAQ
Employees63
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address3001 Daimler Street
CitySanta Ana
ProvinceCalifornia
CountryUnited States of America
Zip Code92705
Phone1-949-396-6830

Company Executives

  • Name
  • Position
  • Salary
  • Paul Song
  • Chief Executive Officer and Director
  • --
  • James A. Graf
  • Director, Interim Chief Financial Officer and Principal Accounting Officer
  • --
  • Yong-man Kim
  • Chief Scientific Officer
  • --
  • Pierre Gagnon
  • Chief Operating Officer
  • --
  • Sangwoo Park
  • Chairman of the Board
  • --
  • Michael Klowden
  • Independent Director
  • --
  • Kathleen D. Scott
  • Independent Director
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg